EPSTEIN-BARR VIRUS (EBV) INFECTION Clinical Trials

10 clinical trials for EPSTEIN-BARR VIRUS (EBV) INFECTION across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) — RECRUITING · PHASE1
• Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection — RECRUITING
• A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES — RECRUITING · PHASE1
• Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia — NOT_YET_RECRUITING · PHASE1
• Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. — NOT_YET_RECRUITING · PHASE1
• A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) — NOT_YET_RECRUITING · PHASE2
• AN OPEN-LABEL, MULTICENTER PHASE 1B/2 STUDY OF NANATINOSTAT AND VALGANCICLOVIR IN PATIENTS WITH ADVANCED EPSTEIN-BARR VIRUS-POSITIVE (EBV+) SOLID TUMORS AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA — COMPLETED · PHASE1
• AN OPEN-LABEL, PHASE 2 TRIAL OF NANATINOSTAT IN COMBINATION WITH VALGANCICLOVIR IN PATIENTS WITH EPSTEIN-BARR VIRUS-POSITIVE (EBV+) RELAPSED/REFRACTORY LYMPHOMAS (NAVAL-1) — COMPLETED · PHASE2
• A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES. SECOND SINGLE-PATIENT CLINICAL TRIAL AT CHU SAINTE-JUSTINE. — NOT_YET_RECRUITING · PHASE1
• Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664). — COMPLETED · PHASE2

Refine this search